Sarepta Therapeutics reported $104.77M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Capricor Therapeutics USD 46K 0 Mar/2025
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Esperion Therapeutics USD 112K 11K Sep/2023
Gilead Sciences USD 1.24B 1000K Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Insmed USD 214.26M 1.67M Dec/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 19K 0 Sep/2024
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novavax USD 1.62M 211K Sep/2024
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Tectonic Therapeutic USD 14.86M 111.83K Dec/2024
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025